Wittens, Mandy M.J.
Denissen, Stijn
Sima, Diana M.
Fransen, Erik
Niemantsverdriet, Ellis
Bastin, Christine
Benoit, Florence
Bergmans, Bruno
Bier, Jean-Christophe
de Deyn, Peter Paul
Deryck, Olivier
Hanseeuw, Bernard
Ivanoiu, Adrian
Picard, Gaëtane
Ribbens, Annemie
Salmon, Eric
Segers, Kurt
Sieben, Anne
Struyfs, Hanne
Thiery, Evert
Tournoy, Jos
van Binst, Anne-Marie
Versijpt, Jan
Smeets, Dirk
Bjerke, Maria
Nagels, Guy
Engelborghs, Sebastiaan
Funding for this research was provided by:
the Interreg V programme Flanders-The Netherlands of the European Regional Development Fund (ERDF)
Flanders Innovation & Intrepreneurship (Baekeland, HBC.2019.2579)
Fonds Wetenschappelijk Onderzoek (1805620N)
Article History
Received: 2 April 2024
Accepted: 4 June 2024
First Online: 14 June 2024
Declarations
:
: The study was approved by the ethics committee of the University of Antwerp / Universitair Ziekenhuis Antwerp (N°16/2/18), Antwerp and by the ethics committees of Algemeen Ziekenhuis Sint-Jan Brugge-Oostende, Bruges (N°1992); Centre Hospitalier Universitaire Brugmann (CHU Brugmann), Brussels (N°2016/84); Centre Hospitalier Universitaire Liège (CHU Liège), Liège (N°2012/274); Cliniques Universitaires de Bruxelles (ULB), Hôpital Erasme, Brussels (N°P2016/187); Cliniques Universitaires Saint-Luc (UCL), Brussels (N°2016/07jui/261); Clinique St-Pierre Ottignies, Ottignies (N°OM045); Universitair Ziekenhuis Brussel, Brussels (N°2016/183); and Ziekenhuis Netwerk Antwerp (ZNA), Antwerp (N°4730). All participants and/or caregivers in case of dementia, gave their written informed consent.icobrain dm is a proprietary software, developed by icometrix for the automated quantification of brain volumes and white matter hyperintensities.
: Not applicable.
: DMS, AR, DS, HS, and MMJW are, or were partially, employed by icometrix during the time of this study. SE serves as a consultant for icometrix, and served as consultant for Biogen, Danone, Eisai, Novartis, Nutricia, Pfizer, and Roche. SD was a PhD candidate in collaboration with icometrix. GN was on a 10% secondment from the UZ Brussel to icometrix during the time of this study and is a minority shareholder of icometrix. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.